Semaglutide for Weight Loss

In June 2021, the U.S. Food and Drug Administration approved Semaglutide (Wegovy) injection (once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity.
 
This under-the-skin injection (subcutaneous) is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014. The drug is indicated for chronic weight management in patients with a body mass index (BMI) of 27 or greater who have at least one weight-related ailment or in patients with a BMI of 30 or greater.
 
Originally used for diabetes and sold under the name Ozempic, a higher dose of the same drug was evaluated for weight loss. The results were dramatic, with the average individual losing 15(+) % of their body weight during the clinic trial. How it works: Semaglutide works by mimicking a hormone called glucagonlike peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake; it is a powerful appetite suppressant. It also works by increasing the production of insulin and appears to enhance growth of β cells in the pancreas, which are the sites of insulin production. Additionally, it inhibits glucagon, which is a hormone that increases blood sugar. It has been known to aid not only in weight loss, but helps to lower glucose levels in those who are pre-diabetic or who have type 2 diabetes.
 

1. Delays stomach emptying, leading to a feeling of fullness and smaller meal size

2. Slows intestinal motility

3. Lowers blood sugars, in part by reducing the production of sugar in the liver

4. Stimulates insulin secretion by the pancreas

 
Since the Semaglutide injection does not help increase energy or boost metabolism, we recommend pairing it with either a vitamin b-12 injection or one of our lipotropic injections (lipo-lean, vita-chrom, or the mega-burn)